Q92750 (TAF4B_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
Transcription initiation factor TFIID subunit 4B

Alternative name(s):
Transcription initiation factor TFIID 105 kDa subunit
Short name=TAF(II)105
Short name=TAFII-105
Short name=TAFII105

Gene names

Name:	TAF4B
Synonyms:	TAF2C2, TAFII105

Organism

Homo sapiens (Human)

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Protein attributes

Sequence length	862 AA.
Sequence status	Complete.
Protein existence	Evidence at protein level

General annotation (Comments)

Function	Cell type-specific subunit of TFIID that may function as a gene-selective coactivator in certain cells. TFIID is a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. TAFII105 is a transcriptional coactivator of the p65/RELA NF-kappa-B subunit. Involved in the activation of a subset of antiapoptotic genes including TNFAIP3. May be involved in regulating folliculogenesis. Through interaction with OCBA/POU2AF1, acts as a coactivator of B cell-specific transcription. Ref.1 Ref.3 Ref.4
Subunit structure	TFIID is composed of TATA binding protein (TBP) and a number of TBP-associated factors (TAFs). Heterodimerizes with TAF12/TFII20 via the C-terminal H2A-like histone-fold domain. This heterodimer forms a histone-like octamer with the TAF6/TAFII70-TAF9/TAFII31 heterodimer. Interacts with P65/RELA homodimers and P65/RELA-REL heterodimers. Interaction with POU2AF1, via its C-terminal activation domain, is required for octamer-dependent transcription. Ref.3 Ref.4 Ref.6
Subcellular location	Nucleus. Cytoplasm. Note: Export into the cytoplasm is mediated by a CRM1-independent nuclear export pathway and not by phosphorylation. Ref.1 Ref.5
Tissue specificity	Preferentially expressed in ovarian granulosa cells (at protein level). Highly expressed in B cells. Ref.1 Ref.2
Post-translational modification	Under stimulation by forskolin, Isoform 1 is phosphorylated by protein kinase A (PKA). Ref.1 Ref.7
Sequence similarities	Belongs to the TAF4 family. Contains 1 histone-fold domain. Contains 1 TAFH (NHR1) domain.

Ontologies

Keywords
Biological process	Transcription Transcription regulation
Cellular component	Cytoplasm Nucleus
Coding sequence diversity	Alternative splicing Polymorphism
Domain	Coiled coil
Ligand	DNA-binding
PTM	Phosphoprotein
Technical term	Complete proteome Direct protein sequencing Reference proteome
Gene Ontology (GO)
Biological process	transcription elongation from RNA polymerase II promoter Traceable author statement. Source: Reactome transcription initiation from RNA polymerase II promoter Traceable author statement. Source: Reactome viral reproduction Traceable author statement. Source: Reactome
Cellular component	cytoplasm Inferred from electronic annotation. Source: UniProtKB-SubCell nucleolus Inferred from direct assay. Source: HPA transcription factor TFIID complex Inferred from electronic annotation. Source: InterPro
Molecular function	DNA binding Inferred from direct assay Ref.6. Source: UniProtKB NF-kappaB binding Inferred from physical interaction Ref.4. Source: UniProtKB sequence-specific DNA binding transcription factor activity Inferred from electronic annotation. Source: InterPro
Complete GO annotation...

Alternative products

This entry describes 2 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: Q92750-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: Q92750-2)

Also known as: TAFII105-E9;

The sequence of this isoform differs from the canonical sequence as follows:
     612-618: DEDDIND → STFICVY
     619-862: Missing.

Note: May be due to exon inclusion. No experimental confirmation available. Unphosphorylated form.

Sequence annotation (Features)

	Feature key	Position(s)	Length	Description	Graphical view	Feature identifier
Molecule processing
	Chain	1 – 862	862	Transcription initiation factor TFIID subunit 4B		PRO_0000118872
Regions
	Domain	256 – 353	98	TAFH
	Domain	653 – 702	50	Histone-fold
	Region	511 – 533	23	Required for interaction with P65/RELA
	Region	516 – 556	41	Nuclear export signal
	Region	830 – 862	33	Required for interaction with TAF12
	Coiled coil	722 – 787	66	Potential
Amino acid modifications
	Modified residue	595	1	Phosphoserine Ref.7
Natural variations
	Alternative sequence	612 – 618	7	DEDDIND → STFICVY in isoform 2.		VSP_022025
	Alternative sequence	619 – 862	244	Missing in isoform 2.		VSP_022026
	Natural variant	249	1	I → V. Corresponds to variant rs16942219 [ dbSNP | Ensembl ].		VAR_052259
	Natural variant	539	1	N → S. Corresponds to variant rs12963653 [ dbSNP | Ensembl ].		VAR_061836
Experimental info
	Sequence conflict	490 – 496	7	SAGTTSD → FCWDHIC in CAA70499. Ref.2
	Sequence conflict	523 – 530	8	QAVQVKQL → TGSSSKQLFSLFH in CAA70499. Ref.2

Sequences

	Sequence		Length	Mass (Da)
	Isoform 1 [UniParc]. Last modified December 12, 2006. Version 2. Checksum: E380D5CD2445AC11	FASTA	862	91,091
	10 20 30 40 50 60 MPAGLTEPAG AAPPAAVSAS GTVTMAPAGA LPVRVESTPV ALGAVTKAPV SVCVEPTASQ 70 80 90 100 110 120 PLRSPVGTLV TKVAPVSAPP KVSSGPRLPA PQIVAVKAPN TTTIQFPANL QLPPGTVLIK 130 140 150 160 170 180 SNSGPLMLVS PQQTVTRAET TSNITSRPAV PANPQTVKIC TVPNSSSQLI KKVAVTPVKK 190 200 210 220 230 240 LAQIGTTVVT TVPKPSSVQS VAVPTSVVTV TPGKPLNTVT TLKPSSLGAS STPSNEPNLK 250 260 270 280 290 300 AENSAAVQIN LSPTMLENVK KCKNFLAMLI KLACSGSQSP EMGQNVKKLV EQLLDAKIEA 310 320 330 340 350 360 EEFTRKLYVE LKSSPQPHLV PFLKKSVVAL RQLLPNSQSF IQQCVQQTSS DMVIATCTTT 370 380 390 400 410 420 VTTSPVVTTT VSSSQSEKSI IVSGATAPRT VSVQTLNPLA GPVGAKAGVV TLHSVGPTAA 430 440 450 460 470 480 TGGTTAGTGL LQTSKPLVTS VANTVTTVSL QPEKPVVSGT AVTLSLPAVT FGETSGAAIC 490 500 510 520 530 540 LPSVKPVVSS AGTTSDKPVI GTPVQIKLAQ PGPVLSQPAG IPQAVQVKQL VVQQPSGGNE 550 560 570 580 590 600 KQVTTISHSS TLTIQKCGQK TMPVNTIIPT SQFPPASILK QITLPGNKIL SLQASPTQKN 610 620 630 640 650 660 RIKENVTSCF RDEDDINDVT SMAGVNLNEE NACILATNSE LVGTLIQSCK DEPFLFIGAL 670 680 690 700 710 720 QKRILDIGKK HDITELNSDA VNLISQATQE RLRGLLEKLT AIAQHRMTTY KASENYILCS 730 740 750 760 770 780 DTRSQLKFLE KLDQLEKQRK DLEEREMLLK AAKSRSNKED PEQLRLKQKA KELQQLELAQ 790 800 810 820 830 840 IQHRDANLTA LAAIGPRKKR PLESGIEGLK DNLLASGTSS LTATKQLHRP RITRICLRDL 850 860 IFCMEQEREM KYSRALYLAL LK
	Isoform 2 (TAFII105-E9) [UniParc]. Checksum: 0EA429488262537F	FASTA	618	63,364
	10 20 30 40 50 60 MPAGLTEPAG AAPPAAVSAS GTVTMAPAGA LPVRVESTPV ALGAVTKAPV SVCVEPTASQ 70 80 90 100 110 120 PLRSPVGTLV TKVAPVSAPP KVSSGPRLPA PQIVAVKAPN TTTIQFPANL QLPPGTVLIK 130 140 150 160 170 180 SNSGPLMLVS PQQTVTRAET TSNITSRPAV PANPQTVKIC TVPNSSSQLI KKVAVTPVKK 190 200 210 220 230 240 LAQIGTTVVT TVPKPSSVQS VAVPTSVVTV TPGKPLNTVT TLKPSSLGAS STPSNEPNLK 250 260 270 280 290 300 AENSAAVQIN LSPTMLENVK KCKNFLAMLI KLACSGSQSP EMGQNVKKLV EQLLDAKIEA 310 320 330 340 350 360 EEFTRKLYVE LKSSPQPHLV PFLKKSVVAL RQLLPNSQSF IQQCVQQTSS DMVIATCTTT 370 380 390 400 410 420 VTTSPVVTTT VSSSQSEKSI IVSGATAPRT VSVQTLNPLA GPVGAKAGVV TLHSVGPTAA 430 440 450 460 470 480 TGGTTAGTGL LQTSKPLVTS VANTVTTVSL QPEKPVVSGT AVTLSLPAVT FGETSGAAIC 490 500 510 520 530 540 LPSVKPVVSS AGTTSDKPVI GTPVQIKLAQ PGPVLSQPAG IPQAVQVKQL VVQQPSGGNE 550 560 570 580 590 600 KQVTTISHSS TLTIQKCGQK TMPVNTIIPT SQFPPASILK QITLPGNKIL SLQASPTQKN 610 RIKENVTSCF RSTFICVY

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"Cyclic AMP-dependent modification of gonad-selective TAF(II)105 in a human ovarian granulosa cell line." Wu Y., Lu Y., Hu Y., Li R. J. Cell. Biochem. 96:751-759(2005) [PubMed: 16088961] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY. Tissue: Ovarian carcinoma.
[2]	"Human TAFII 105 is a cell type-specific TFIID subunit related to hTAFII130." Dikstein R., Zhou S., Tjian R. Cell 87:137-146(1996) [PubMed: 8858156] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 67-862 (ISOFORM 1), PROTEIN SEQUENCE OF 81-85; 242-253; 281-290; 302-310; 377-388; 473-479; 507-522; 580-587; 675-689; 697-712 AND 746-800, TISSUE SPECIFICITY.
[3]	"Specific interaction of TAFII105 with OCA-B is involved in activation of octamer-dependent transcription." Wolstein O., Silkov A., Revach M., Dikstein R. J. Biol. Chem. 275:16459-16465(2000) [PubMed: 10828057] [Abstract] Cited for: INTERACTION WITH POU2AF1, FUNCTION.
[4]	"Interaction of TAFII105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes." Yamit-Hezi A., Nir S., Wolstein O., Dikstein R. J. Biol. Chem. 275:18180-18187(2000) [PubMed: 10849440] [Abstract] Cited for: INTERACTION WITH P65/RELA AND REL, FUNCTION.
[5]	"A composite nuclear export signal in the TBP-associated factor TAFII105." Rashevsky-Finkel A., Silkov A., Dikstein R. J. Biol. Chem. 276:44963-44969(2001) [PubMed: 11567023] [Abstract] Cited for: SUBCELLULAR LOCATION, NUCLEAR EXPORT SIGNAL.
[6]	"Core promoter binding by histone-like TAF complexes." Shao H., Revach M., Moshonov S., Tzuman Y., Gazit K., Albeck S., Unger T., Dikstein R. Mol. Cell. Biol. 25:206-219(2005) [PubMed: 15601843] [Abstract] Cited for: INTERACTION WITH TAF12 IN A COMPLEX WITH TAF6; TAF9; TAF12 AND TAF4B, DNA-BINDING.
[7]	"Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach." Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S. Anal. Chem. 81:4493-4501(2009) [PubMed: 19413330] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-595, MASS SPECTROMETRY. Tissue: Embryonic kidney.
+	Additional computationally mapped references.

Cross-references

Sequence databases
EMBL GenBank DDBJ	AY888048 mRNA. Translation: AAX14897.1. AY888049 mRNA. Translation: AAX14898.1. Y09321 mRNA. Translation: CAA70499.1.
IPI	IPI00646423. IPI01010820.
RefSeq	NP_005631.1. NM_005640.1.
UniGene	Hs.369519.
3D structure databases
ProteinModelPortal	Q92750.
SMR	Q92750. Positions 653-700.
ModBase	Search...
Protein-protein interaction databases
IntAct	Q92750. 2 interactions.
STRING	Q92750.
PTM databases
PhosphoSite	Q92750.
Polymorphism databases
DMDM	119370533.
Proteomic databases
PRIDE	Q92750.
Protocols and materials databases
StructuralBiologyKnowledgebase	Search...
Genome annotation databases
Ensembl	ENST00000269142; ENSP00000269142; ENSG00000141384.
GeneID	6875.
KEGG	hsa:6875.
UCSC	uc002kvt.2. human.
Organism-specific databases
CTD	6875.
GeneCards	GC18P023806.
H-InvDB	HIX0039751.
HGNC	HGNC:11538. TAF4B.
HPA	HPA028937.
MIM	601689. gene.
neXtProt	NX_Q92750.
PharmGKB	PA36313.
GenAtlas	Search...
Phylogenomic databases
eggNOG	prNOG06197.
GeneTree	ENSGT00390000011620.
HOVERGEN	HBG103779.
InParanoid	Q92750.
OrthoDB	EOG4CJVH7.
Enzyme and pathway databases
Reactome	REACT_1788. Transcription. REACT_6185. HIV Infection. REACT_71. Gene Expression.
Gene expression databases
ArrayExpress	Q92750.
Bgee	Q92750.
CleanEx	HS_TAF4B.
Genevestigator	Q92750.
Family and domain databases
InterPro	IPR009072. Histone-fold. IPR007900. TAF4. IPR003894. TAFH_NHR1. [Graphical view]
Gene3D	G3DSA:1.10.20.10. Histone-fold. 1 hit.
KO	K03129.
Pfam	PF05236. TAF4. 1 hit. PF07531. TAFH. 1 hit. [Graphical view]
SMART	SM00549. TAFH. 1 hit. [Graphical view]
SUPFAM	SSF47113. Histone-fold. 1 hit.
PROSITE	PS51119. TAFH. 1 hit. [Graphical view]
ProtoNet	Search...
Other
NextBio	26841.
SOURCE	Search...

Entry information

Entry name

TAF4B_HUMAN

Accession

Primary (citable) accession number: Q92750
Secondary accession number(s): Q29YA4, Q29YA5

Entry history

Integrated into UniProtKB/Swiss-Prot:	July 15, 1998
Last sequence update:	December 12, 2006
Last modified:	January 25, 2012
This is version 102 of the entry and version 2 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.